When did Spyre Therapeutics, Inc. report Q4 2024 earnings?

Spyre Therapeutics, Inc. (SYRE) reported Q4 2024 earnings on February 27, 2025 before market open.

What were Spyre Therapeutics, Inc.'s Q4 2024 revenue and EPS?

Spyre Therapeutics, Inc. reported revenue of - and eps of $-0.81 for Q4 2024.

Did Spyre Therapeutics, Inc. beat estimates in Q4 2024?

EPS beat the consensus estimate of $-0.89 by $0.08.

Where can I find Spyre Therapeutics, Inc.'s Q4 2024 SEC filings?

You can read the 10-K periodic report (0001636282-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.

Spyre Therapeutics, Inc. SYRE Q4 2024 Annual earnings

Reported February 27, 2025 · Before market open

Revenue-

EPS-$0.81Beat by $0.08

EPS estimate-$0.89

Next report

Aug 4, 2026 (In 6 days)

EPS estimate-$0.71

Financials

Q4 2024

Income statement

See full

Revenue-—

Operating income-$61.3M-33.4%

Net income-$56.3M+10.9%

EPS (diluted)-$0.24—

Balance sheet

See full

Cash & equivalents$89.4M-52.7%

Total equity$517.8M+181%

Total assets$608.5M+78.0%

Cash flow

See full

Operating cash flow-$37.2M-19.9%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation & ratios

Valuation

as of 12/31/24

See full

Market cap$1.39B+79.6%

Returns & leverage

See full

Return on equity-59.3%-26.3pp

Current ratio11.3×+0.6×

Segments

By segment

See full

Reportable Segment--100%

Versus estimates

Revenue

Q4 2025$90.5MMiss by $52.4M

Diluted EPS

Q1 2026-$0.74Miss by $0.08 Q4 2025-$0.70Miss by $0.04 Q3 2025-$0.15Beat by $0.53 Q2 2025-$0.49Beat by $0.24 Q1 2025-$0.74Beat by $0.02

Q4 2024-$0.81Beat by $0.08

Ask the moment Spyre Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI

Claude

Questions, answered.

When did Spyre Therapeutics, Inc. report Q4 2024 earnings?: Spyre Therapeutics, Inc. (SYRE) reported Q4 2024 earnings on February 27, 2025 before market open.
What were Spyre Therapeutics, Inc.'s Q4 2024 revenue and EPS?: Spyre Therapeutics, Inc. reported revenue of - and eps of $-0.81 for Q4 2024.
Did Spyre Therapeutics, Inc. beat estimates in Q4 2024?: EPS beat the consensus estimate of $-0.89 by $0.08.
Where can I find Spyre Therapeutics, Inc.'s Q4 2024 SEC filings?: You can read the 10-K periodic report (0001636282-25-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.